Literature DB >> 2474627

Nonbactericidal antibodies against Neisseria gonorrhoeae: evaluation of their blocking effect on bactericidal antibodies directed against outer membrane antigens.

M Virji1, J E Heckels.   

Abstract

Nonbactericidal monoclonal antibodies (MAbs) directed against gonococcal surface antigens were examined for their effect on complement-mediated bactericidal killing by other MAbs and normal human serum. One MAb, SM73, directed against the H.8 antigen activated complement only moderately well and had little influence on bactericidal antibodies. Two antibodies directed against an epitope on protein III had very different effects. Antibody SM51 activated complement poorly and had no effect on bactericidal killing, whereas antibody SM50, although itself nonbactericidal, activated complement and blocked the bactericidal effect of other antibodies. The extent of the blocking ability of MAb SM50 was studied using MAbs of different specificities as well as polyclonal antisera raised against gonococcal surface antigens. Antibody SM50 blocked IgG MAbs of all specificities, but several MAbs of the IgM class retained their bactericidal effect. Each of these IgM MAbs reacted with lipopolysaccharide, but with different epitopes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2474627     DOI: 10.1099/00221287-134-10-2703

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  9 in total

1.  Functional activities and epitope specificity of human and murine antibodies against the class 4 outer membrane protein (Rmp) of Neisseria meningitidis.

Authors:  E Rosenqvist; A Musacchio; A Aase; E A Høiby; E Namork; J Kolberg; E Wedege; A Delvig; R Dalseg; T E Michaelsen; J Tommassen
Journal:  Infect Immun       Date:  1999-03       Impact factor: 3.441

2.  Bacterial [Cu,Zn]-cofactored superoxide dismutase protects opsonized, encapsulated Neisseria meningitidis from phagocytosis by human monocytes/macrophages.

Authors:  Kate L R Dunn; Jayne L Farrant; Paul R Langford; J Simon Kroll
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

3.  Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein.

Authors:  Sunita Gulati; Sarika Agarwal; Shreekant Vasudhev; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

4.  Underlying Glycans Determine the Ability of Sialylated Lipooligosaccharide To Protect Nontypeable Haemophilus influenzae from Serum IgM and Complement.

Authors:  Mary Darby Jackson; Sandy M Wong; Brian J Akerley
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

Review 5.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

6.  Antibody to reduction modifiable protein increases the bacterial burden and the duration of gonococcal infection in a mouse model.

Authors:  Sunita Gulati; Xin Mu; Bo Zheng; George W Reed; Sanjay Ram; Peter A Rice
Journal:  J Infect Dis       Date:  2015-01-16       Impact factor: 5.226

7.  Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins.

Authors:  Tathagat Dutta Ray; Lisa A Lewis; Sunita Gulati; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2011-03-14       Impact factor: 5.422

8.  New concepts in immunity to Neisseria gonorrhoeae: innate responses and suppression of adaptive immunity favor the pathogen, not the host.

Authors:  Yingru Liu; Brandon Feinen; Michael W Russell
Journal:  Front Microbiol       Date:  2011-03-22       Impact factor: 5.640

9.  Binding of complement factor H to loop 5 of porin protein 1A: a molecular mechanism of serum resistance of nonsialylated Neisseria gonorrhoeae.

Authors:  S Ram; D P McQuillen; S Gulati; C Elkins; M K Pangburn; P A Rice
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.